Back to Top Skip to main content

Measles-Mumps-Rubella

Frequently Asked Questions (FAQ) about the current measles outbreak
and MMR vaccine policy and recommendations

Measles

Measles disease picture

Measles is a highly contagious acute viral respiratory illness caused by a single-stranded, enveloped RNA virus with 1 serotype. Humans are the only natural hosts of measles virus.

Transmission of the measles virus is through direct contact with infectious droplets or by airborne spread when an infected person breathes, coughs, or sneezes. Measles virus can remain infectious in the air for up to two hours after an infected person leaves an area.

Clinical features include a prodrome marked by high fever followed by the onset of cough, runny nose, and red, watery eyes (conjunctivitis). Koplik spots may be seen on mucous membranes in the mouth; these lesions present as blue and white spots on bright red background and appear a few days before and after the measles rash. The characteristic measles rash appears as maculopapular lesions that start on the head and gradually proceed down the body over 5-6 days.

Complications develop in approximately 30% of measles cases, which are most common in children younger than 5 years and adults 20 years and older. Complications include ear infections, diarrhea, pneumonia, or encephalitis (brain inflammation), and rarely death.

There is no cure for measles. Treatment is symptomatic and supportive.

Mumps

Mumps disease picture

Mumps is an acute viral illness caused by an enveloped RNA virus that belongs to the genus Rubulavirus, in the family Paramyxoviridae.  Humans are the only natural hosts for mumps virus, which is usually spread by respiratory droplets, saliva, or contact with contaminated fomites. The incubation period of mumps averages 16–18 days, with a range of about 2–4 weeks.

Mumps infection may present with primarily respiratory symptoms or may be asymptomatic. However, clinical features of mumps usually include unilateral or bilateral, parotitis, with single or multiple salivary glands affected. Parotitis occurs within the first 2 days and may first be noted as earache and tenderness on palpation of the angle of the jaw. Symptoms tend to decrease after 1 week and usually resolve after 10 days. Nonspecific prodromal symptoms may precede parotitis by several days, including low-grade fever which may last three to four days, myalgia, anorexia, malaise, and headache.

Complications of mump infections are more likely to be serious when adults are infected. Complications of mumps can include meningitis (in up to 15% of cases), orchitis, and deafness. Very rarely, mumps can cause encephalitis and permanent neurological damage.

Rubella

Rubella disease pictureRubella, also called German measles, is a contagious viral infection caused by rubella virus.  Humans are the only natural hosts of rubella virus, which is transmitted through person-to-person contact or droplets shed from the respiratory secretions of infected people. People may shed virus from 7 days before the onset of the rash to approximately 5–7 days after rash onset. Transmission from mother to fetus can also occur, with the highest risk of congenital rubella syndrome (CRS) if infection occurs in the first trimester. Infants with CRS can transmit virus for up to 1 year after birth. 

Symptoms of rubella are often mild, and up to 50% of infections may be subclinical or inapparent.  Rubella usually presents as a nonspecific, maculopapular, generalized rash that lasts ≤3 days with generalized lymphadenopathy. Rash may be preceded by low-grade fever, malaise, anorexia, mild conjunctivitis, runny nose, and sore throat. Adolescents and adults, especially women, can also present with transient arthritis. Infection during early pregnancy can lead to miscarriage, fetal death, or the fetus can develop Congenital Rubella Syndrome (CRS), which can affect virtually all organ systems, with deafness being the most common outcome. Up to 85% of infants are affected if infection occurs during the first trimester of pregnancy.

Complications of rubella are not common, and generally occur more often in adults than in children.  Arthralgia or arthritis may occur in up to 70% of adult women who contract rubella, and tend to occur about the same time or shortly after appearance of the rash, lasting for up to 1 month.  Additional complications that can occur are encephalitis, orchitis, neuritis, and a late syndrome of progressive panencephalitis. Complications that do occur more often in children than adults are hemorrhagic manifestations (approximately one per 3,000 cases) that may be secondary to low platelets and vascular damage, with thrombocytopenic purpura being the most common manifestation. Gastrointestinal, cerebral, or intrarenal hemorrhage may occur. Effects may last from days to months, and most patients recover.

M-M-R®II is a live-virus vaccine which includes antigens for measles, mumps, and rubella, licensed for persons 12 months and older. Two doses of MMR vaccine are routinely recommended for children, starting with the first dose at age 12 through 15 months and the second dose at age 4 through 6 years before school entry. Children can receive the second dose earlier as long as it is at least 28 days after the first dose.

Teens and adults should also be up to date on MMR vaccinations. MMR vaccination is especially important for:

  • Students at post-high school educational institutions
  • International travelers
  • Healthcare professionals
  • Women of childbearing age who are not pregnant
  • People who care for or are around immunocompromised people
  • People living with HIV without evidence of severe immunosuppression

After vaccination, it is not necessary to test patients for antibodies to confirm immunity.

ProQuad® (MMRV) is a live-virus combination vaccine which includes antigens for measles, mumps, rubella, and varicella. ProQuad® is licensed for children 12 months through 12 years of age. If MMRV vaccine is used, at least 3 months should elapse between doses of varicella-containing vaccine.

You also may be interested in...

Measles Myths: Vaccines Are Safe

Video
9/17/2019
Measles Myths: Vaccines Are Safe

Vaccine components have been rigorously tested for safety. Dr. Margaret Ryan, preventive medicine physician, debunks some myths about vaccinations.

Recommended Content:

Preventive Health | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella

Measles Myths: Vaccines Do Not Cause Autism

Video
9/12/2019
Measles Myths: Vaccines Do Not Cause Autism

Vaccines that prevent measles do not cause autism. Dr. Margaret Ryan, preventive medicine physician, debunks some myths about vaccinations.

Recommended Content:

Preventive Health | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella | Autism Care Demonstration

Measles Frequently Asked Questions

Publication
7/11/2019

Answers to frequently asked questions (FAQs) related to measles outbreaks and the latest vaccine recommendations, in downloadable, printable memorandum format.

Recommended Content:

Measles-Mumps-Rubella

Notes from the Field: Measles Outbreaks from Imported Cases in Orthodox Jewish Communities — New York and New Jersey, 2018–2019

Report
5/17/2019

Measles outbreaks in New York and New Jersey occurred after unvaccinated travelers reported recent travel to Israel, where a measles outbreak of more than 3,000 cases is ongoing.

Recommended Content:

Measles-Mumps-Rubella

Notes from the Field: Community Outbreak of Measles — Clark County, Washington, 2018–2019

Report
5/17/2019

A measles outbreak has affected dozens in Washington, and of approximately 3,800 contacts of infected patients, 22 percent lacked acceptable presumptive evidence of measles immunity.

Recommended Content:

Measles-Mumps-Rubella

Cold Chain Management of Measles, Mumps, Rubella Vaccine

Fact Sheet
5/14/2019

This information paper describes the cold chain management of the Measles, Mumps, Rubella Vaccine

Recommended Content:

Vaccine Storage and Handling | Measles-Mumps-Rubella

Progress Toward Measles Elimination — European Region, 2009–2018

Report
5/3/2019

By end of 2017, 70 percent of European Region countries were verified to have eliminated endemic measles. During 2017–2018, however, a resurgence of measles occurred, with large-scale outbreaks in Ukraine, Serbia, and some countries that had achieved elimination.

Recommended Content:

Measles-Mumps-Rubella

Increase in Measles Cases — United States, January 1–April 26, 2019

Report
4/29/2019

A total of 704 cases of measles have been reported in the United States this year, the highest number reported since 1994. Outbreaks in underimmunized, close-knit communities accounted for 88 percent of all cases.

Recommended Content:

Measles-Mumps-Rubella

Notes from the Field: Measles Outbreak in an Era of Stricter Immunization Requirements — California, March 2018

Report
3/1/2019

In a 2018 outbreak in California, six unvaccinated patients with measles all had parents who had chosen not to vaccinate them during childhood. Since 2016, children entering school in California may no longer receive exemptions from immunization requirements based on parental personal beliefs. However, interviews with local health authorities suggest that some students without contraindications to vaccination have received medical exemptions.

Recommended Content:

Measles-Mumps-Rubella

Measles 2019

Infographic
2/20/2019
This infographic discusses the symptoms of measles and how to prevent it

This infographic highlights the symptoms of measles and how getting vaccinated can prevent the disease.

Recommended Content:

Measles-Mumps-Rubella

Notes From The Field: Mumps Outbreak in a Recently Vaccinated Population — Kosrae, Federated States of Micronesia, August–December, 2017

Report
2/1/2019

A recent mumps outbreak totaled 23 mumps cases, 21 of which occurred in patients with two documented doses of MMR vaccine. Investigations of recent mumps outbreaks suggest that waning of vaccine-induced immunity might contribute to transmission in populations with high MMR vaccination coverage.

Recommended Content:

Measles-Mumps-Rubella

Progress Toward Regional Measles Elimination — Worldwide, 2000–2017

Report
11/30/2018

Measles incidence decreased 83 percent, and annual estimated measles deaths decreased 80 percent since 2000. Global measles elimination efforts have prevented an estimated 21.1 million total deaths. However, three regions are experiencing a large measles resurgence.

Recommended Content:

Measles-Mumps-Rubella

Global Routine Vaccination Coverage — 2017

Report
11/16/2018

Global coverage with vaccines to prevent diphtheria, tetanus, pertussis, polio, and measles has remained at 84%–85% since 2010. Prioritizing countries with the highest number of unvaccinated children to implement context-specific strategies has the potential to increase immunization coverage globally.

Recommended Content:

Immunization Healthcare | Measles-Mumps-Rubella | Polio | Tetanus-Diphtheria-Pertussis

Measles Outbreak in a Highly Vaccinated Population — Israel, July–August 2017

Report
10/26/2018

During July and August 2017, nine measles cases occurred among vaccinated Israeli soldiers. The primary patient had recently traveled to Europe. All other cases occurred in his direct contacts. All patients had mild illness; no tertiary cases occurred.

Recommended Content:

Measles-Mumps-Rubella

Mumps Outbreak in a Marshallese Community — Denver Metropolitan Area, Colorado, 2016–2017

Report
10/19/2018

An outbreak of 47 mumps cases occurred in the Denver metropolitan area, mostly among members of a Marshallese community. Public health response included early active surveillance, public education, and prompt implementation of MMR vaccination clinics.

Recommended Content:

Measles-Mumps-Rubella
<< < 1 2 3 > >> 
Showing results 1 - 15 Page 1 of 3

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.